SciMar NuPa Daily's mission as part of the SciMar family is to prevent the risk of Type 2 diabetes and promote community and individual well-being.
Rooted in 25+ years of in-depth scientific research, our new approach is being unleashed to counter the widespread Type 2 diabetes crisis by redefining the liver's role as central in understanding, preventing, managing, and ultimately reversing Type 2 diabetes.
SciMar NuPa Daily is more than a groundbreaking supplement steeped in powerful science. It is the cornerstone of SciMar's mission to eradicate Type 2 diabetes by changing the conversation and shifting the scientific paradigm. 100% of the proceeds from sales of SciMar NuPa Daily will be directed toward community wellness outreach initiatives and ongoing lab research and clinical trials toward the fulfillment of our mission.
The scientists at SciMar are actively sharing their knowledge with the global scientific community, and are committed to developing ongoing research and outreach initiatives to end Type 2 diabetes.
SciMar NuPa Daily was born out of a paradigm-changing discovery made by our founder, Dr. W. Wayne Lautt, in 1996: the liver plays a central role in Type 2 diabetes.
Many of Dr. W. Wayne Lautt's experiments used a unique combination of antioxidants as a scientific tool to test hypotheses and protect the liver function of test subjects. These ingredients demonstrated enormous protective qualities, so Dr. W. Wayne Lautt began to develop a product that could be used outside of the lab.
In our preclinical studies we observed the significant capacity of this formulation to protect the body's ability to partition nutrients into muscle and away from fat and reduce the combined effects of age, stress, a sedentary lifestyle, and a high-fat/high-sugar diet.
Through its potent and patented blend of ingredients, SciMar NuPa Daily delivers the essential antioxidants our modern lifestyle needs at the beginning of your day, kickstarting your journey to a healthier, happier you.
SciMar NuPa Daily is the product of ingenuity, rigor, and passion. The SciMar team comprises accomplished scientists and skilled managers bonded together by a sincere desire to contribute positively to global well-being, to inspire people to take charge of their health, and to change the conversation about metabolic health and Type 2 diabetes.
Under the leadership of award-winning scientist Dr. W. Wayne Lautt, the SciMar lab team includes experts in clinical trial leadership, liver function, pharmaceuticals, nutrition, exercise, molecular biology, data analysis, cell culture analysis, and mass spectrometry.
Supporting our staff team is a network of 25+ experts and suppliers in the United States and Canada who provide expertise in patents, trademarks, intellectual property, manufacturing, regulatory affairs, marketing, e-commerce, shipping, logistics, and clinical trial management.
Dr. W. Wayne Lautt
Prof. Emeritus at the University of Manitoba; Founder, Chief Scientific Officer, SciMar Ltd.
Mick Lautt
Chief Executive Officer, SciMar Ltd.
John West
Chief Development Officer, SciMar Ltd.
While SciMar NuPa Daily is a supplement that almost everyone can take, the future of the NuPa product line is dedicated to meeting people's needs at all stages of Type 2 diabetes progression.
Through this research, SciMar has developed novel products to diagnose, support, and reverse any damage to the hepatalin* hormone along with a synthetic version of the hormone itself.
A nutraceutical for metabolism, immunity, and mood balance that is believed to protect the production of hepatalin.
Measures the body's ability to produce hepatalin, thereby detecting Type 2 diabetes earlier than ever possible before.
A prescription drug that activates the production of hepatalin.
SciMar Ltd. is developing a synthetic version of hepatalin in a way that can be used along with insulin as a new combined treatment.
